EODData

MEMBERSHIP REGISTER LOG IN

NYSE, BHVN: Biohaven Ltd

21 Nov 25 13:34
LAST:

9.990

CHANGE:
 0.32		OPEN:
9.500		HIGH:
10.040		ASK:
24.950		VOLUME:
1.33M
CHG(%):
3.31		PREV:
9.670		LOW:
9.295		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Nov 259.50010.0409.2959.9901.33M
20 Nov 259.67010.2809.5309.6305.04M
19 Nov 259.2409.4958.9509.4603.92M
18 Nov 258.2509.7008.2309.4507.21M
17 Nov 258.6408.7857.9908.2704.13M
14 Nov 258.0008.3707.8108.3004.82M
13 Nov 257.8408.5407.7808.0807.96M
12 Nov 257.7708.5807.7507.95012.22M
11 Nov 257.7308.7707.4808.5205.87M
10 Nov 258.4508.5107.6457.7904.23M

PROFILE

Name:Biohaven Ltd
About:Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:215 Church Street, New Haven, CT, United States, 06510
Website:https://www.biohaven.com
CIK:0001689813
ISIN:VGG111961055
FIGI:BBG017BXV3Q9
LEI:5299007STZTNN32O9920

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.60 
Forward P/E:-2.35 
PEG Ratio:0.03 
Price to Book:11.67 
Return on Assets:-1.03 
Return on Equity:-2.96 
EPS Ratio:-7.46 
Shares:105.79M 
Market Cap:1.057B 

TECHNICAL INDICATORS

MA5:9.337.1%
MA10:8.7314.5%
MA20:11.4214.4%
MA50:13.8738.8%
MA100:14.2342.5%
MA200:18.5385.4%
STO9:80.47 
STO14:28.97
RSI14:26.46 
WPR14:-66.96
MTM14:-4.13
ROC14:-0.30 
ATR:1.27 
Week High:10.282.9%
Week Low:7.8127.9%
Month High:18.5785.8%
Month Low:7.4885.4%
Year High:47.75378.0%
Year Low:7.4833.6%